Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 36,425 shares of the pharmaceutical company’s stock after selling 4,173 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $4,694,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in VRTX. Korea Investment CORP boosted its position in shares of Vertex Pharmaceuticals by 225.3% in the first quarter. Korea Investment CORP now owns 950 shares of the pharmaceutical company’s stock valued at $104,000 after buying an additional 658 shares in the last quarter. Guardian Life Insurance Co. of America boosted its position in shares of Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co boosted its position in shares of Vertex Pharmaceuticals by 7.1% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,500 shares of the pharmaceutical company’s stock valued at $164,000 after buying an additional 100 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $197,000. Finally, Koshinski Asset Management Inc. acquired a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $220,000. 93.13% of the stock is currently owned by institutional investors.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at 153.78 on Friday. The firm has a 50-day moving average of $143.85 and a 200 day moving average of $115.44. The company has a market capitalization of $38.77 billion, a P/E ratio of 147.72 and a beta of 1.77. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.86.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.33. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. During the same period last year, the company posted $0.24 EPS. The company’s quarterly revenue was up 26.1% compared to the same quarter last year. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Sells 4,173 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2017/08/12/mitsubishi-ufj-kokusai-asset-management-co-ltd-sells-4173-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.

Several analysts recently issued reports on VRTX shares. UBS AG reiterated a “buy” rating and set a $135.00 price target (up previously from $132.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Cowen and Company reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Sunday, April 30th. Vetr upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $181.00 price target on the stock in a research report on Monday, July 31st. Finally, Maxim Group set a $195.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Five equities research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $162.88.

In other news, SVP Paul M. Silva sold 1,289 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $152.88, for a total value of $197,062.32. Following the completion of the sale, the senior vice president now directly owns 17,923 shares of the company’s stock, valued at approximately $2,740,068.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey M. Leiden sold 147,101 shares of the firm’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $129.50, for a total transaction of $19,049,579.50. Following the completion of the sale, the chief executive officer now directly owns 312,142 shares of the company’s stock, valued at $40,422,389. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 751,042 shares of company stock valued at $113,078,257. Corporate insiders own 1.80% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.